Aravive, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2024-10-31: Study NCT05826015; Company role Collaborator; Phase Phase 1; Status Withdrawn.
- 2021-07-28: Study NCT04983407; Company role Lead sponsor; Phase Phase 1, Phase 2; Status Terminated.
- 2021-06-30: Study NCT03607955; Company role Collaborator; Phase Phase 1; Status Withdrawn.
- 2021-04-22: Study NCT04729608; Company role Lead sponsor; Phase Phase 3; Status Terminated.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2024-10-31 | NCT05826015 AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer | Collaborator Lead: Washington University School of Medicine | Phase 1 | Withdrawn | Recurrent High Grade Uterine Cancer | 0 | 2034-06-04 |
| 2021-07-28 | NCT04983407 Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma | Lead sponsor | Phase 1, Phase 2 | Terminated | Pancreatic Adenocarcinoma | 34 | 2023-08-14 |
| 2021-06-30 | NCT03607955 Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy | Collaborator Lead: Washington University School of Medicine | Phase 1 | Withdrawn | Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer | 0 | 2029-08-31 |
| 2021-04-22 | NCT04729608 Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer | Lead sponsor | Phase 3 | Terminated | Platinum-resistant Ovarian Cancer | 366 | 2023-08-04 |
| 2021-02-26 | NCT04300140 Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma | Lead sponsor | Phase 1, Phase 2 | Terminated | Clear Cell Renal Cell Carcinoma | 72 | 2023-08-14 |
| 2020-02-17 | NCT04004442 Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma | Collaborator Lead: University of Oklahoma | Phase 1 | Active not recruiting | Urothelial Carcinoma | 19 | 2026-10 |
| 2019-11-27 | NCT04042623 Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy | Lead sponsor | Phase 2 | Terminated Results posted | IgA Nephropathy | 1 | 2020-08-01 |
| 2018-12-06 | NCT03639246 Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer | Lead sponsor | Phase 1 | Completed | Ovarian Cancer | 53 | 2022-12-30 |
| 2018-01-31 | NCT03401528 A Phase 1 AVB-S6-500 Safety and Tolerability Study | Lead sponsor | Phase 1 | Completed | Healthy Volunteer | 43 | 2018-07-31 |
| 2017-03-31 | NCT03145831 A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency | Lead sponsor | Phase 3 | Terminated | Growth Hormone Deficiency | 21 | 2017-11-30 |
| 2016-02-11 | NCT02719990 Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD) | Lead sponsor | Phase 2 | Terminated Results posted | Adult Growth Hormone Deficiency (AGHD) | 36 | 2018-01-11 |
| 2015-08-26 | NCT02339090 Long-Acting Growth Hormone in Children Compared to Daily rhGH | Lead sponsor | Phase 3 | Completed Results posted | Growth Disorders | 138 | 2017-08-23 |
| 2015-08-08 | NCT02413138 Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317) | Lead sponsor | Phase 2, Phase 3 | Terminated | Pediatric Growth Hormone Deficiency; Growth Disorders | 41 | 2017-11-30 |
| 2015-07 | NCT02526420 Versartis International Trial in Adults With Long-Acting Growth Hormone | Lead sponsor | Phase 2 | Completed | Adult Growth Hormone Deficiency | 36 | 2016-10 |
| 2014-03-03 | NCT02068521 Versartis Long-Term Safety Study of Somavaratan | Lead sponsor | Phase 2, Phase 3 | Terminated | Pediatric Growth Hormone Deficiency | 385 | 2017-11-17 |
| 2012-10 | NCT01718041 Versartis Trial in Children to Assess Long-Acting Growth Hormone | Lead sponsor | Phase 1, Phase 2 | Completed | Pediatric Growth Hormone Deficiency | 64 | 2014-07 |
| 2011-03 | NCT01359488 VRS-317 in Adult Subjects With Growth Hormone Deficiency | Lead sponsor | Phase 1 | Completed | Growth Hormone Deficiency | 50 | 2012-07 |